Although CD20-directed B cell depletion has long been used in neuromyelitis optica spectrum disorder (NMOSD), high-quality, large-scale, randomized controlled trials remain limited. In this multicenter, randomized, double-blind phase 3 trial, we evaluated obinutuzumab β (MIL62), a novel glycoengineered type II anti-CD2...
Lei Wu, Liangliang Gu, Wei-Hao Fan et al.· Nature Medicine· 1 citation
Ischemic white matter injury and the consequent neuroimmune response can contribute to vascular cognitive impairment. The role of B cells in ischemic white matter injury is unclear. Here, we show that crosstalk between meningeal B cells and CNS-resident microglia exacerbates white matter injury and vascular cognitive i...
Inebilizumab demonstrated real‐world effectiveness and a manageable safety profile in a diverse population of patients with AQP4‐IgG‐seropositive NMOSD, supporting the findings of the pivotal N‐MOmentum trial.
Meng-Cui Gui, Jiayang Zhan, Wei Li et al.· Annals of Clinical and Trans...· 0 citations
Extracellular vesicles (EVs) are crucial mediators of intercellular communication and have the potential to serve as biomarkers for disease diagnosis and therapeutic monitoring. However, most EV isolation methods often require large sample volumes and specialized instruments or involve trade-offs between purity, yield,...
Li Sun, L. Duke, Cynthia Vied et al.· ACS Nano· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
